1 Introduction
2 Goal of the review
3 Resveratrol, a plant-derived polyphenol
3.1 Resveratrol‘s natural sources and chemical properties
3.2 Bioavailability, absorption, and metabolism of resveratrol
4 Resveratrol’s versatile anti-carcinogenic effects
4.1 Resveratrol’s effect on different cancer types
Subcellular signaling / Mechanism | References | |
---|---|---|
Down-regulation of | Transcription factor signaling pathway | |
- NF-κB signaling pathway | ||
- HIF-1α signaling pathway | ||
- MAPK signaling pathway | ||
- AP-1 signaling pathway | ||
- STAT3 signaling pathway | ||
- β-Catenin signaling pathway | ||
- Cell cycle signaling pathway | ||
- Growth factor signaling pathway | ||
- Mitochondrial signaling pathway | ||
- Inflammation signaling pathway | ||
- Oxidative signaling pathway | ||
- Mutagenesis signaling pathway | ||
- Angiogenesis signaling pathway | [140] | |
- Plasticity/Migration signaling pathway | ||
- Estrogen signaling pathway | ||
- RANKL signaling pathway | ||
- Apoptosis signaling pathway | ||
Up-regulation of | Transcription factors signaling pathway | |
- Sox9 signaling pathway | ||
- Scleraxis signaling pathway | [163] | |
- PPAR-γ/RUNX2 signaling pathway | ||
- PI3K/Akt/mTOR signaling pathway | ||
- p53 signaling pathway | ||
- Autophagy signaling pathway | ||
- Apoptosis signaling pathway | ||
- Estrogen signaling pathway | ||
- Maintenance of the cellular signaling pathway | ||
- Immunomodulatory signaling pathway |
4.2 Resveratrol modulates inflammation and acts anti-carcinogenic in CRC cells
Signal modulating networks | Kind of test, CRC cell- /animal Type | Mode of action | References |
---|---|---|---|
Suppression of pro-inflammatory cytokines in CRC | In vitro, HCT-116, HCT-116R cells | Modulation of TNF-β signaling pathway, suppression of NF-κB activation | [80] |
In vitro and in vivo, LoVo cells and Mice | Inhibition of inflammation, EMT through TGF-β1/Smads signaling, suppression of metastasis and plasticity in CRC cells | [196] | |
In vitro, HCT-116/ RKO/SW480 cells | Inhibition of TNF-β/TNF-β-receptor-induced activation of NF-κB, NF-κB-promoted gene products | [199] | |
In vivo, Rat | Inhibition of neutrophil infiltration, cytokines and oxidative stress, reduction of colitis | [215] | |
In vivo, Mice | Modified gut microcosm leads to anti-inflammatory response and alleviation of inflammation-promoted CRC | [216] | |
Suppression of inflammation, proliferation and tumor formation / induction of apoptosis in CRC | In vitro, HT-29/WiDr cells | Inhibition of inflammation and proliferation in CRC cells | [217] |
In vitro, HCT-116 cells | Inhibition of Wnt/survivin signaling, inflammation, activation of p53-independent apoptosis | [218] | |
In vitro, HCT-116/RKO/SW480 cells | Inhibition of TNF-β/TNF-βR-induced EMT via suppression of NF-κΒ, FAK and plasticity | ||
In vitro, HCA17/SW480/HT-29 cells | Inhibition of inflammation, proliferation and apoptosis in CRC cells | [219] | |
In vitro, HCT-116/Caco-2 cells | Inhibition of proliferation by inducing G1/S-phase cell cycle arrest, apoptosis by caspase/cyclin-CDK pathways | [220] | |
In vitro, HCT-116/CO115 cells | Activation of p53-mediated apoptosis, inhibition of inflammation | [221] | |
In vitro, DLD1/HCT-15 cells | Inhibition of inflammation and proliferation by targeting the Akt/STAT3 signaling pathway | [123] | |
In vivo, Rat | Inhibition of DMH-induced irregular crypt lesion foci, CRC formation, increased expression of anti-oxidant enzymes | [222] | |
In vivo, Mice | Inhibition of CRC formation and inflammation | [89] | |
In vivo, Rat | Inhibition of CRC occurrence through regulation of inflammatory enzymes, growth of aberrant crypt lesions | [223] | |
In vivo, Rat | Inhibition of precancerous lesions in the colon and inflammation | [224] | |
In vivo, Mice | Inhibition of intestinal tumorigenesis by reducing genes involved in cell proliferation and inflammation | [225] | |
In vitro and in vivo, HCT-116 cells and Mice | Resveratrol with curcumin inhibited CRC cell growth more effectively than either agent alone, associated with reduction of inflammation, proliferation, stimulation of apoptosis, together with a decrease in NF-κB activity | [226] | |
In vivo, Mice | Inhibition of PGE2, COX-2 expression and the number of adenomas | [227] | |
In vivo, Rat | Inhibition of CRC, inflammation and aberrant crypt foci by targeting Bax and p21 expression | [228] | |
In vivo, IRC mice | Inhibition of iNOS, NF-κB, STAT3, and ERK expressions | [208] | |
In vitro, HCT-116 and DLD1 cells | Inhibition of Akt/STAT3 and NFκB | [209] | |
In vitro, DLD1 and HCT-15 cells | Inhibition of Akt/STAT3, cyclin D1, cyclin E2, and Bcl-2, increase of p53 | [123] | |
In vitro, HT-29 and SW-620 cells | Inhibition of Akt and STAT3, induction of ROS | [210] | |
In vitro, HCT-116 cells | Inhibition of COX-2 in both miRNA and protein levels | [211] | |
In vitro, HT-29 cells | Inhibition of NO and PGE2 production, iNOS and COX-2 expression and ROS, suppression of JAK/STAT and SAPK/JNK pathways | [212] | |
In vivo, HT-29 colon cancer xenograft using nude mice | Resveratrol+ginkgetin enhanced the anti-tumor effect of 5-FU via decrease in microvessel density of tumors, suppressing expressions of COX-2, TNF-α and IL-6 | [213] | |
In vitro and in vivo, 2D and 3D model of HCT-116 cells murine subcutaneous xenograft HCT-116 model | Micro-immunotherapy medicine + resveratrol induced immunomodulation of macrophages, decrease in the volume of 3D spheroids, decrease in the volume of xenografts | [214] |
5 Resveratrol acts as a chemosensitizer in CRC cells
5.1 Difficulty of chemoresistance in CRC cells
Drug | Pathway or related enzyme/protein | Type of study | Effects and possible mechanisms of chemoresistance | References |
---|---|---|---|---|
5-Fluorouracil (5-FU) | Thymidylate synthase (TS) | Meta-analysis, 20 studies, 3497 CRC patients | ↑TS expression leading to; ↑5-FU target inhibition and ↓5-FU sensitivity | |
In vitro, SNU-C1 parental and SNU-C1 (5-FU resistant) | ↑TS mRNA expression; ↑TS activity | [253] | ||
Clinical, formalin-fixed paraffin-embedded specimens, 132 CRC patients (Dukes’ B=36 cases, Dukes’ C=60 cases, Dukes’ B=36 cases) | ↑TS expression correlated to 5-FU resistance, shorter recurrence free-interval, and reduced overall survival | [254] | ||
Clinical, tissue samples (normal, primary, and liver metastases), digital karyotyping | ↑Gene amplification of TS major mechanism of 5-FU resistance | [255] | ||
Clinical, PCR analysis of genomic DNA, 121 CRC patients | ↑TS expression associated with poor response to 5-FU | [256] | ||
Inhibitor of DNA binding 1, HLH protein (ID1) | In vitro, CRC-stem-like cells; In vivo, mice xenograft model | ↑ID1 (stemness marker) expression | [257] | |
p53 related apoptosis | In vitro, HCT-116 | ↓p53 correlated to; ↑5-FU resistance and ↓apoptosis | [258] | |
RhoGDI2 and apoptosis | In vitro, LoVo | ↑RhoGDI2; ↑CapG; ↓Maspin; ↓Apoptosis | [259] | |
SHMT2 and autophagy | Clinical, paired-frozen-primary samples (CRC and adjacent normal tissue), 50 patients; clinical, paraffin-embedded samples, 378 patients; In vivo, mouse xenograft model | ↓SHMT2; ↓SHMT2 binding of cytosolic p53; ↓Apoptosis; ↑Pro-survival autophagy, ↑Plasticity | ||
p38-MAPK, apoptosis, and autophagy | In vitro, RKO, HT-29, LoVo, SW620 and HCT-116 | ↓p38-MAPKα; ↓Apoptosis; ↑Autophagy | [261] | |
RAC3, apoptosis, and autophagy | In vitro, HT-29, LoVo and HCT-116 | ↑RAC3; ↓Apoptosis; ↓Autophagy | [262] | |
TGF-β and EMT | In vitro, HCT-116, HCT-116p53KO and HT-29; In vivo, mice xenograft model | ↑TGF-β; ↑Proliferation; ↓Cell death; ↑Plasticity | [263] | |
OPRT-RR and TP-TK pathways | In vitro, SW48 and LS174T (parental and resistant) | In SW48-5-FUR cells - ↓OPRT; ↓TP; ↓FdUMP; ↓Drug sensitivity; ↑IC50 In LS174T-5-FUR cells - ↓OPRT; ↓RR; ↑TK; ↑dTMP; ↓Drug sensitivity; ↑IC50 | [264] | |
Hedgehog pathway | In vitro, LoVo (parental and resistant) | ↑GLI1; ↑IC50 for 5-FU | [265] | |
Irinotecan (SN-38; irinotecan metabolite) | ABCC1/MRP1, ABCC2/MRP2, ABCG2/BCRP, multi-drug resistance protein (MDR/MRP) | In vitro, HCT-116 | ↑Expression of MDR/MRP proteins; ↑Drug efflux; ↑Plasticity | |
ABCG2/BCRP, multi-drug resistance protein (MDR/MRP) | In vitro, HCT-116, S1-IR20 (novel irinotecan resistant CRC cell line) | ↑ABCG2/BCRP; ↑Drug efflux | ||
ATP7A, copper transporter | Clinical, 50 patients with advanced CRC | ↑ATP7A; ↑Drug efflux; ↑Drug uptake in membrane vesicles | [269] | |
Oxaliplatin | OCT, drug intake | In vitro, LS180, SW620, DLD, HT20, RKO and HCT-116 | ↓OCT1 (SLC22A1); ↓OCT2 (SLC22A2); ↓Oxaliplatin sensitivity | [270] |
CHK2, DNA repair | In vitro, HT-29, LoVo, Colo201 and Colo205; In vivo, mice xenograft model | ↑phosphorylated CHK2 (pCHK2T68); ↑Homologous recombination repair pathways; ↑DNA repair; ↑CHK2/PARP1 interaction | [271] | |
ABGC2, a multi-drug resistance protein (MDR/MRP) | In vitro, LoVo (parental and resistant) | ↑ABGC2; ↓G2 cell-cycle arrest; ↑phosphorylated NF-κB; ↓ER stress; ↓Apoptosis | [272] | |
Nrf2, oxidative stress | In vitro, HCT-116 and SW620 | ↑Nrf2; ↑Nrf2 regulated gene expression; ↓Proliferation; ↑IC50 for various drugs | [273] | |
Cetuximab | KRAS WT tumors | Clinical, 220 chemorefractory metastatic CRC (cmCRC) patients | ↑EREG; ↑AREG; ↓Survival | [274] |
EGFR somatic sequence alterations (G465R, G465E, S468R, S492R) | In vitro, LIM1215 and OXCO-2 | ↓mAb binding; ↓EGFR pathway inhibition | [275] | |
EGFR mutation (pS492R) | Clinical; plasma samples from 1010 patients with metastatic CRC | ↓mAb binding; ↓EGFR pathway inhibition | [276] |
5.2 Chemoresistance through tumor cell plasticity in CRC cells
5.3 Resveratrol’s chemosensitizing effect by modulation of tumor cell plasticity in CRC cells
5.4 Resveratrol’s further chemosensitizing effects on CRC cells
Drug | CRC cell line/cancer model | Chemosensitizing/resensitizing effect of resveratrol in a combinatory therapeutic approach | References |
---|---|---|---|
5-Fluorouracil (5-FU) | DLD1 and HCT-116 cells | ↓Akt signaling pathway; ↓Cellular proliferation and migration; ↑S-phase cell-cycle arrest; ↑Apoptosis; ↓Slug and vimentin (EMT signaling factors); ↓Stemness; ↓STAT3 binding to hTERT promoter site, ↓Plasticity | [209] |
HT-29 and SW620 cells | ↑Mitochondrial oxidative stress; ↓Akt; ↓STAT3 | [210] | |
HCT-116 and HCT-116R* cells | ↑Apoptosis (caspase-3); ↓Vimentin and slug, while ↑E-cadherin (EMT factors); ↓CSC phenotype (CD133, CD44, ALDH1); ↓TNFβ induced activation of NF-κB, MMP9, CXCR4 | [80] | |
HCT-116, HCT-116R*; SW480 and SW480R* cells | ↓Cell proliferation; ↓Cell invasion; ↑Cell-cell contact (↑ desmosomes, gap- and tight-junctions); ↑E-cadherin; ↓Vimentin and slug; ↓NF-κB activation and nuclear translocation; ↓NF-κB driven genes (MMP9, caspase-3) | [79] | |
HCT-116 and HCT-116R* cells | ↓β1-integrin/HIF1α axis B activation; ↓TME promoted viability; ↓Proliferation; ↓Colony formation; ↓Invasion tendency; ↓EMT; ↓NF-κB; ↓VEGF; ↓HIF1α; ↓Stem cell markers (CD44, CD133, ALDH1); ↑Caspase-3; ↑Apoptosis | [319] | |
Cetuximab | HCT-116 and CT-26 (mouse cell line) cells | ↓Growth; ↑Cx43 expression and phosphorylation; ↑Gap junction function; ↓Akt; ↓NF-κB, ↓Plasticity | [320] |
Doxorubicin (Adriamycin) | Caco-2 cells | ↓P-gp and MDR1; ↓Drug-efflux/extrusion from cells; ↓ CYP3A4 and GST (drug metabolizing enzymes); ↑Caspases-3, -8 and -9; ↑Apoptosis | [321] |
HT-29 and HCT-116 cells | ↓IC50 of doxorubicin; ↑Bax; ↑Apoptosis; ↑S-phase cell-cycle arrest; ↓P-gp, ↓Plasticity | [322] | |
Oxaliplatin | Caco-2 cells | ↓Cell proliferation; ↓Growth; ↓Survivin; ↑PARP cleavage; ↑Caspase-3 activity; ↑Apoptosis, ↓Plasticity | [323] |
Drug | CRC cell line/cancer model | Anti-chemosensitizing effect of resveratrol in a combinatory therapeutic approach | References |
Oxaliplatin | HCT-116 cells | ↑Survivin; ↓Apoptosis, ↓Plasticity | [324] |
6 Insights of clinical resveratrol application in CRC patients
# of CRC Patients | Study phase | Resveratrol application | Resveratrol’s effects | Signaling target | Year of publication | Reference |
---|---|---|---|---|---|---|
9 | 1 | 5g SRT501 (microparticular, in sachets)/day, for 10–21 day | Resveratrol was well-tolerated and was detected in blood plasma as well as hepatic tissue affected by metastases. It induced an up-regulation (39%) of apoptosis in malignant tissue. | Apoptosis, caspase-3 | 2011 | [327] |
20 | 1 | 0.5g or 1g (caplets)/day, for 8 days | Resveratrol was well-tolerated and reduced (p=0.05) CRC cell proliferation. | Proliferation, Ki-67 | 2010 | [35] |
12 selected, 8 completed | 1 | 20mg or 80mg (tablets)/day, for 14 days | Resveratrol was well tolerated and inhibited significantly (p<0.03) the CRC initiation in normal colonic mucosa. | Initiation, Wnt signaling gene | 2009 | [328] |